Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955217 | 0.85 | CA2 (0.43) | MAPTTDP1KDM4EALDH1A1HPGD | |
| SCHEMBL28474445 | 0.85 | LMNA (0.38) | CYP19A1TDO2ALDH1A1HPGDCA12 | |
| SCHEMBL23771985 | 0.85 | HPGD (0.38) | MAPTTDP1CYP19A1TDO2KDM4E | |
| SCHEMBL8501513 | 0.83 | TUBB4A (0.32) | MAPTTDP1CYP19A1TDO2CYP1A1 | |
| SCHEMBL14200084 | 0.83 | ALDH1A1 (0.40) | MAPTTDP1KDM4EALDH1A1HPGD | |
| SCHEMBL5299248 | 0.82 | AOC3 (0.37) | MAPTTDP1CYP19A1KDM4EALDH1A1 | |
| SCHEMBL11649084 | 0.81 | TSHR (0.46) | MAPTTDP1KDM4EALDH1A1RAB9A | |
| SCHEMBL2589167 | 0.80 | TSHR (0.37) | MAPTTDP1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL3674074 | 0.76 | CA9 (0.50) | MAPTTDP1CYP19A1KDM4EALDH1A1 | |
| SCHEMBL30701949 | 0.76 | CA9 (0.50) | MAPTTDP1CYP19A1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | MAPT 1061/4885TDP1 2521/4885CYP19A1 4404/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | MAPT 3255/4885TDP1 2411/4885CYP19A1 3900/4885 |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | NFATC1, GZMB, ICOS | MAPT 1061/4885TDP1 2521/4885CYP19A1 4404/4885 |
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | MAPT 2419/4885TDP1 3319/4885CYP19A1 4289/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | MAPT 1714/4885TDP1 2399/4885CYP19A1 4311/4885 |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | MAPT 2419/4885TDP1 3319/4885CYP19A1 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.